Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells

The multikinase inhibitor, sorafenib, is a first-line treatment for hepatocellular carcinoma (HCC), but its limited efficacy, drug resistance and toxicity are a concern. In this study, we investigated the role of lncRNA TP53TG1 in the efficacy of sorafenib in HCC cells. We found that treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Qingchun, Xin, Mingyang, Guo, Qian, Rothberg, Brad S., Gamero, Ana M., Yang, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414591/
https://www.ncbi.nlm.nih.gov/pubmed/36005829
http://dx.doi.org/10.3390/ncrna8040061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414591/
https://www.ncbi.nlm.nih.gov/pubmed/36005829
http://dx.doi.org/10.3390/ncrna8040061

Ejemplares similares